These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 24033880)

  • 1. Japanese guidance for use of biologics for psoriasis (the 2013 version).
    Ohtsuki M; Terui T; Ozawa A; Morita A; Sano S; Takahashi H; Komine M; Etoh T; Igarashi A; Torii H; Asahina A; Nemoto O; Nakagawa H;
    J Dermatol; 2013 Sep; 40(9):683-95. PubMed ID: 24033880
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Japanese guidance for use of biologics for psoriasis (the 2019 version).
    Saeki H; Terui T; Morita A; Sano S; Imafuku S; Asahina A; Komine M; Etoh T; Igarashi A; Torii H; Abe M; Nakagawa H; Watanabe A; Yotsuyanagi H; Ohtsuki M;
    J Dermatol; 2020 Mar; 47(3):201-222. PubMed ID: 31916326
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and effectiveness of ustekinumab and antitumour necrosis factor therapy in patients with psoriasis and chronic viral hepatitis B or C: a retrospective, multicentre study in a clinical setting.
    Navarro R; Vilarrasa E; Herranz P; Puig L; Bordas X; Carrascosa JM; Taberner R; Ferrán M; García-Bustinduy M; Romero-Maté A; Pedragosa R; García-Diez A; Daudén E
    Br J Dermatol; 2013 Mar; 168(3):609-16. PubMed ID: 22985451
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sequential use of biologics in the treatment of moderate-to-severe plaque psoriasis.
    Leman J; Burden AD
    Br J Dermatol; 2012 Nov; 167 Suppl 3():12-20. PubMed ID: 23082811
    [TBL] [Abstract][Full Text] [Related]  

  • 5. English version of Japanese guidance for use of biologics for psoriasis (the 2022 version).
    Saeki H; Mabuchi T; Asahina A; Abe M; Igarashi A; Imafuku S; Okubo Y; Komine M; Sano S; Torii H; Morita A; Yotsuyanagi H; Watanabe A; Ohtsuki M;
    J Dermatol; 2023 Feb; 50(2):e41-e68. PubMed ID: 36582113
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment effect of adalimumab and infliximab in Japanese psoriasis patients: results in a single community-based hospital.
    Noda S; Mizuno K; Adachi M
    J Dermatol; 2012 Mar; 39(3):265-8. PubMed ID: 22126280
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effective and sustainable biologic treatment of psoriasis: what can we learn from new clinical data?
    Langley RG
    J Eur Acad Dermatol Venereol; 2012 Mar; 26 Suppl 2():21-9. PubMed ID: 22356632
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-adalimumab and anti-infliximab antibodies developed in psoriasis vulgaris patients reduced the efficacy of biologics: report of two cases.
    Matsumoto Y; Maeda T; Tsuboi R; Okubo Y
    J Dermatol; 2013 May; 40(5):389-92. PubMed ID: 23414225
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety of biologics in psoriasis.
    Kamata M; Tada Y
    J Dermatol; 2018 Mar; 45(3):279-286. PubMed ID: 29226369
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of neutralizing antibodies to adalimumab and infliximab on the treatment of psoriasis.
    Bito T; Nishikawa R; Hatakeyama M; Kikusawa A; Kanki H; Nagai H; Sarayama Y; Ikeda T; Yoshizaki H; Seto H; Adachi A; Horikawa T; Oka M; Nishigori C
    Br J Dermatol; 2014 Apr; 170(4):922-9. PubMed ID: 24329764
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug survival is not significantly different between biologics in patients with psoriasis vulgaris: a single-centre database analysis.
    Menting SP; Sitaram AS; Bonnerjee-van der Stok HM; de Rie MA; Hooft L; Spuls PI
    Br J Dermatol; 2014 Oct; 171(4):875-83. PubMed ID: 24673245
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Ustekinumab in a patient with Crohn's disease and anti-TNF-α-induced psoriasis].
    Sansó Sureda A; Rocamora Durán V; Sapiña Camaró A; Royo Escosa V; Bosque López MJ
    Gastroenterol Hepatol; 2011 Oct; 34(8):546-50. PubMed ID: 21665330
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety observations in 12095 patients with psoriasis enrolled in an international registry (PSOLAR): experience with infliximab and other systemic and biologic therapies.
    Gottlieb AB; Kalb RE; Langley RG; Krueger GG; de Jong EM; Guenther L; Goyal K; Fakharzadeh S; Chevrier M; Calabro S; Langholff W; Menter A
    J Drugs Dermatol; 2014 Dec; 13(12):1441-8. PubMed ID: 25607786
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum interleukin-22 and vascular endothelial growth factor serve as sensitive biomarkers but not as predictors of therapeutic response to biologics in patients with psoriasis.
    Shimauchi T; Hirakawa S; Suzuki T; Yasuma A; Majima Y; Tatsuno K; Yagi H; Ito T; Tokura Y
    J Dermatol; 2013 Oct; 40(10):805-12. PubMed ID: 23915382
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Successful treatment of psoriasis with ustekinumab in patients with multiple sclerosis.
    Chang S; Chambers CJ; Liu FT; Armstrong AW
    Dermatol Online J; 2015 Jul; 21(7):. PubMed ID: 26436967
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of psoriasis scalp with alopecia during treatment of Crohn's disease with infliximab and rapid response to both diseases to ustekinumab.
    Andrisani G; Marzo M; Celleno L; Guidi L; Papa A; Gasbarrini A; Armuzzi A
    Eur Rev Med Pharmacol Sci; 2013 Oct; 17(20):2831-6. PubMed ID: 24174369
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Costs of therapy with biologics in the treatment of moderate to severe plaque psoriasis in the context of the Italian health-care system.
    Terranova L; Mattozzi C; Richetta AG; Mantuano M; Cardosi L; Teruzzi C
    G Ital Dermatol Venereol; 2014 Feb; 149(1):131-43. PubMed ID: 24566574
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris.
    Gniadecki R; Kragballe K; Dam TN; Skov L
    Br J Dermatol; 2011 May; 164(5):1091-6. PubMed ID: 21219290
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-drug antibodies in psoriasis: a critical evaluation of clinical significance and impact on treatment response.
    Hsu L; Armstrong AW
    Expert Rev Clin Immunol; 2013 Oct; 9(10):949-58. PubMed ID: 24128157
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The status of biologic therapies in the treatment of moderate to severe psoriasis.
    Menter A
    Cutis; 2009 Oct; 84(4 Suppl):14-24. PubMed ID: 19916298
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.